Hydroxychloroquine, the anti-malarial drug has been creating quite the stir. Donald Trump has been pushing the drug, encouraging patients to take it. India also agreed to lift a ban on the drug hours after the US President hinted at a possible retaliation. A report by the New York Times now suggests that Trump himself has a 'small personal financial interest' in Sanofi, the French pharmaceutical company makes Plaquenil, the brand-name version of hydroxychloroquine. The report also suggests that several other pharmaceutical companies also stand to profit - including those with shareholders that have connections to Trump.